

QIBA Process Coordinating Committee

March 25, 2015 at 3:00 PM CT

Call Summary

Attendees:

Kevin O'Donnell, MASC (Chair)
Daniel Sullivan, MD (Vice-chair)
Michael Boss, PhD

Edward Jackson, PhD
Eric Perlman, MD
Nickolas Petrick, PhD

Staff:

Joe Koudelik
Susan Weinmann

General Discussion

- The group discussed the latest version of the template for the QIBA conformance statement (dated 03 15 2015).
- 2 different types of conformance statement were suggested:
 - Products/vendor (hardware and software)
 - Humans and sites (i.e., interaction)
- Mr. O'Donnell will add new discussion topics for template review on Google Docs based on feedback received from biomarker committee members
- Profile editors encouraged to generalize conformance details to be more applicable across multiple modalities/groups.
- The issue of whether profiles should be organ-specific was discussed. Both CT Vol and DWI are facing this. In principle, the requirements and procedures of a given profile might be equally applicable to a variety of organs, but the performance targets and groundwork evidence would need to address all the organs in the claim. Ultimately, it's probably a choice for the Profiling Committee to evaluate.
- The group began to clarify details that are appropriate for inclusion in the annex.
- We need to consider who we expect to publish QIBA Conformance Statements, and to whom are they making claims of conformance?
 - Certainly vendors will publish conformance statements about their products to inform their customers/purchasers.
 - Investigators might also publish conformance statements about their site to inform Clinical Trialists of trials they are participating in.
 - There are probably more scenarios.
- The incorporation of geography details discussed regarding imaging sites and their satellite centers (i.e., how far reaching is the conformance statement?)

Next Call: Wednesday, April 8, 2015 at 3 PM CT